ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens-Reference-Cited by-同舟云学术

ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens

Published:2020-08-20 Issue:9 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Squires Katherine E.¹^ORCID,Mayers Douglas L.¹,Bluemling Gregory R.²³,Kolykhalov Alexander A.²,Guthrie David B.²,Reddy Prabhakar²,Mitchell Debbie G.²,Saindane Manohar T.²,Sticher Zachary M.²,Edpuganti Vindhya²,De La Rosa Abel¹

Affiliation:

1. Antios Therapeutics, Inc., Atlanta, Georgia, USA

2. Emory Institute for Drug Development (EIDD), Atlanta, Georgia, USA

3. Drug Innovation Ventures at Emory (DRIVE), Atlanta, Georgia, USA

Abstract

ATI-2173 is a novel liver-targeted molecule designed to deliver the 5′-monophosphate of clevudine for the treatment of chronic hepatitis B infection. Unlike other nucleos(t)ides, the active clevudine-5′-triphosphate is a noncompetitive, non-chain-terminating inhibitor of hepatitis B virus (HBV) polymerase that delivers prolonged reduction of viremia in both a woodchuck HBV model and in humans for up to 6 months after cessation of treatment. However, long-term clevudine treatment was found to exhibit reversible skeletal myopathy in a small subset of patients and was subsequently discontinued from development.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00836-20

Reference47 articles.

1. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma

2. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

3. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine

4. Identification and Characterization of Clevudine-Resistant Mutants of Hepatitis B Virus Isolated from Chronic Hepatitis B Patients

5. Hepatitis B cure: From discovery to regulatory approval

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of New Targets for Hepatitis B Virus;Clinics in Liver Disease;2023-11

2. What is the Path Forward to Treat Hepatitis Delta Virus?;Clinics in Liver Disease;2023-11

3. Hepatitis B Virus Epsilon (ε) RNA Element: Dynamic Regulator of Viral Replication and Attractive Therapeutic Target;Viruses;2023-09-12

4. Advancing beyond reverse transcriptase inhibitors: The new era of hepatitis B polymerase inhibitors;European Journal of Medicinal Chemistry;2023-09

5. Recent Advances in Molecular Mechanisms of Nucleoside Antivirals;Current Issues in Molecular Biology;2023-08-17